David Carbone, MD is a Professor of Internal Medicine at the The Ohio State University and is a co-leader of the Translational Therapeutics Program at The Ohio State University Comprehensive Cancer Center (OUSCCC).
Prof. Carbone obtained his MD and PhD in Molecular Biology and Genetics from Johns Hopkins University, Baltimore, MD. He then completed an internship and subsequently a residency in internal medicine at Johns Hopkins Medical Center, before completing a fellowship in medical oncology at the National Cancer Institute in Bethesda, MD. He previously held positions as Assistant Professor at the University of Texas Southwestern Medical Center, Dallas, TX and Professor of Medicine, Cell Biology, and Cancer Biology at the Vanderbilt University Medical Center, Nashville, TN.
Prof. Carbone has served on several National Cancer Institute (NCI) grant review panels and the NCI Board of Scientific Counselors. He has also been a President of the International Association for the Study of Lung Cancer (IASLC), holds the Barbara J. Bonner Chair in Lung Cancer Research, and is the current co-chair of the NCI CTEP Thoracic Malignancies Steering Committee.
Speaking on genetics, immunotherapy and tumor-associated immunosuppression mechanisms in lung cancer
Prof. Carbone is an active researcher, having authored more than 250 peer-reviewed publications. Specifically, his recent work has focused on the development of molecular biomarkers to guide patient management and therapy and the molecular profiling of lung cancers and pre-neoplasias to guide the development of therapeutics, especially using mass spectrometry-based proteomics. He has served as an investigator on multiple clinical trials, including the Phase III TRINITY study of rovalpituzumab tesirine in DLL3-expressing non-small cell lung cancer.